Emmanuel Meyer

USPTO Granted Patents = 12 (Patent Applications = 2)

CIPO Patents = 12 (Patent Applications = 3)

EPO Patents = 14 (Patent Applications = 12)

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 58(Granted Patents)

Location History:

Aarau, CH (2011 - 2013)
Allschwil, CH (2012 - 2019)

Company Filing History:

8 out of 217

Actelion Pharmaceuticals Ltd

patents

4 out of 77

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2011-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10259807 - 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives (2019-04-16),

2. 10053457 - Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators (2018-08-21),

3. 10047080 - (R)-2-methyl-piperazine derivatives as CXCR3 receptor modulators (2018-08-14),

4. 9951063 - 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives (2018-04-24),

5. 9266876 - 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives (2016-02-23),

6. 8664203 - Thiazole derivatives and their use as P2Y12 receptor antagonists (2014-03-04),

7. 8518912 - [object Object] (2013-08-27),

8. 8466156 - 2-phenyl-4-cyclopropyl-pyrimidine derivatives (2013-06-18),

9. 8288385 - 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines (2012-10-16),

10. 8058263 - Substituted 2-phenyl-pyridine derivatives (2011-11-15),

11. 8048881 - Pyrimidine derivatives and their use as P2Y12 receptor antagonists (2011-11-01),

12. 8044055 - 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor (2011-10-25),

Title: Emmanuel Meyer: Innovator in Pharmaceutical Chemistry

Introduction

Emmanuel Meyer is a distinguished inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 12 patents. His work primarily focuses on developing compounds that serve as modulators for the CXCR3 receptor, which has implications in various medical applications.

Latest Patents

Among his latest patents, one notable invention is the development of 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives. This invention relates to compounds of Formula (I), wherein specific variables are defined in the description. These compounds, along with their pharmaceutically acceptable salts, are utilized as medicaments, particularly as modulators of the CXCR3 receptor. Another significant patent involves hydroxyalkyl-piperazine derivatives, which also act as CXCR3 receptor modulators, showcasing the versatility and importance of his research.

Career Highlights

Emmanuel Meyer has worked with prominent companies in the pharmaceutical industry, including Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Emmanuel has collaborated with notable colleagues such as Eva Caroff and Kurt Hilpert. These partnerships have further enriched his work and expanded the impact of his inventions.

Conclusion

Emmanuel Meyer stands out as a key figure in pharmaceutical innovation, with a strong portfolio of patents that reflect his expertise and dedication to advancing medical science. His contributions continue to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.